EUA for bamlanivimab revoked April 16 2021 FDA letter press release

Submitted by vgreene on Mon, 05/16/2022 - 19:28
Exclude Patient Type Detail Header
No
Detail Type
Text
Patient Type Detail Header (Long)
EUA for bamlanivimab revoked April 16, 2021 (<a href=https://www.fda.gov/media/147629/download?utm_medium=email&utm_source=govdelivery><b><u>FDA letter</u></b></a>, <a href=https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-monoclonal-antibody-bamlanivimab><b><u>press release</u></b></a>)